Literature DB >> 21470203

The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

R Baur1, J Gertsch, E Sigel.   

Abstract

BACKGROUND AND
PURPOSE: Rimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments. We intended to show that these drugs did not act at GABA(A) receptors but found a significant positive allosteric modulation instead. EXPERIMENTAL APPROACH: Recombinant GABA(A) receptors were expressed in Xenopus oocytes. Receptors were exposed to AM251 or rimonabant in the absence and presence of GABA. Standard electrophysiological techniques were used to monitor the elicited ionic currents. KEY
RESULTS: AM251 dose-dependently potentiated responses to 0.5 µM GABA at the recombinant α(1) β(2) γ(2) GABA(A) receptor with an EC(50) below 1 µM and a maximal potentiation of about eightfold. The Hill coefficient indicated that more than one binding site for AM251 was located in this receptor. Rimonabant had a lower affinity, but a fourfold higher efficacy. AM251 potentiated also currents mediated by α(1) β(2) , α(x) β(2) γ(2) (x = 2,3,5,6), α(1) β(3) γ(2) and α(4) β(2) δ GABA(A) receptors, but not those mediated by α(1) β(1) γ(2) . Interestingly, the CB(1) receptor antagonists LY320135 and O-2050 did not significantly affect α(1) β(2) γ(2) GABA(A) receptor-mediated currents at concentrations of 1 µM. CONCLUSIONS AND IMPLICATIONS: This study identified rimonabant and AM251 as positive allosteric modulators of GABA(A) receptors. Thus, potential GABAergic effects of commonly used concentrations of these compounds should be considered in in vitro experiments, especially at extrasynaptic sites where GABA concentrations are low. LINKED ARTICLES: This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21470203      PMCID: PMC3423234          DOI: 10.1111/j.1476-5381.2011.01405.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  The Xenopus oocyte: system for the study of functional expression and modulation of proteins.

Authors:  Erwin Sigel; Frédéric Minier
Journal:  Mol Nutr Food Res       Date:  2005-03       Impact factor: 5.914

Review 2.  The endocannabinoid system: a drug discovery perspective.

Authors:  Daniele Piomelli
Journal:  Curr Opin Investig Drugs       Date:  2005-07

Review 3.  Endocannabinoids and synaptic function in the CNS.

Authors:  Yuki Hashimotodani; Takako Ohno-Shosaku; Masanobu Kano
Journal:  Neuroscientist       Date:  2007-04       Impact factor: 7.519

Review 4.  GABAA receptor channels.

Authors:  R L Macdonald; R W Olsen
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

5.  LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.

Authors:  C C Felder; K E Joyce; E M Briley; M Glass; K P Mackie; K J Fahey; G J Cullinan; D C Hunden; D W Johnson; M O Chaney; G A Koppel; M Brownstein
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

6.  Properties of single sodium channels translated by Xenopus oocytes after injection with messenger ribonucleic acid.

Authors:  E Sigel
Journal:  J Physiol       Date:  1987-05       Impact factor: 5.182

7.  Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'.

Authors:  Andrew Gardner; Paul E Mallet
Journal:  Eur J Pharmacol       Date:  2005-12-27       Impact factor: 4.432

8.  Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.

Authors:  S J Gatley; R Lan; B Pyatt; A N Gifford; N D Volkow; A Makriyannis
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

Review 9.  Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

Authors:  George Kunos
Journal:  Am J Med       Date:  2007-09       Impact factor: 4.965

10.  Attenuation of allergic contact dermatitis through the endocannabinoid system.

Authors:  Meliha Karsak; Evelyn Gaffal; Rahul Date; Lihua Wang-Eckhardt; Jennifer Rehnelt; Stefania Petrosino; Katarzyna Starowicz; Regina Steuder; Eberhard Schlicker; Benjamin Cravatt; Raphael Mechoulam; Reinhard Buettner; Sabine Werner; Vincenzo Di Marzo; Thomas Tüting; Andreas Zimmer
Journal:  Science       Date:  2007-06-08       Impact factor: 47.728

View more
  15 in total

1.  The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Authors:  A Chicca; J Marazzi; J Gertsch
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

3.  Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.

Authors:  Michael W Calik; David W Carley
Journal:  Sleep       Date:  2017-09-01       Impact factor: 5.849

4.  Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.

Authors:  Palmi Modi; Shivani Patel; Mahesh Chhabria
Journal:  Mol Divers       Date:  2022-08-15       Impact factor: 3.364

5.  The biarylpyrazole compound AM251 alters mitochondrial physiology via proteolytic degradation of ERRα.

Authors:  Susan M Krzysik-Walker; Isabel González-Mariscal; Morten Scheibye-Knudsen; Fred E Indig; Michel Bernier
Journal:  Mol Pharmacol       Date:  2012-10-12       Impact factor: 4.436

6.  Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.

Authors:  Hassan Abbassian; Benjamin J Whalley; Vahid Sheibani; Mohammad Shabani
Journal:  Br J Pharmacol       Date:  2016-10-04       Impact factor: 8.739

7.  Effects of the cannabinoid CB₁ receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats.

Authors:  Li Jing; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

8.  The major central endocannabinoid directly acts at GABA(A) receptors.

Authors:  Erwin Sigel; Roland Baur; Ildiko Rácz; Janine Marazzi; Trevor G Smart; Andreas Zimmer; Jürg Gertsch
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 9.  Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

Authors:  Maureen L Petrunich-Rutherford; Michael W Calik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  CB1R activation in nucleus accumbens core promotes stress-induced reinstatement of cocaine seeking by elevating extracellular glutamate in a drug-paired context.

Authors:  Andrea S Guzman; Maria P Avalos; Laura N De Giovanni; Pia V Euliarte; Marianela A Sanchez; Bethania Mongi-Bragato; Daiana Rigoni; Flavia A Bollati; Miriam B Virgolini; Liliana M Cancela
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.